Latest Commercialization News

Solvar Limited reported a 5.8% rise in net profit for the half year ending December 2025, driven by strategic asset sales and expanded funding facilities. The company declared both interim and special dividends, signalling confidence despite ongoing regulatory challenges.

Horseshoe Metals has announced a significant new copper Exploration Target at its Motters Zone within the Horseshoe Lights Project, estimating up to 3.6 million tonnes grading 1.5% copper. This development highlights the potential to substantially expand the existing resource base as Phase 2 drilling and commercial discussions advance.

Cleo Diagnostics has chosen Bio-Techne’s next-generation Ella™ platform to enhance its ovarian cancer blood test, aiming for faster, more precise results and a streamlined path to FDA approval.

Schaffer Corporation’s first half FY26 profit fell sharply due to a Jaguar Land Rover cyberattack disrupting production, while its South Connect Jandakot property development breaks ground.

Star Minerals has entered a strategic partnership with Catalyst Metals, securing a gold milling agreement for its Tumblegum South project and selling its West Bryah Basin copper-gold assets for $2.75 million. Catalyst also commits to a $1 million equity placement in Star Minerals, underpinning the company’s development plans.

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

SHAPE Australia Corporation Limited has reported a robust first half of FY26, with significant gains in revenue, profits, and project pipeline, underpinned by strategic sector diversification and a key acquisition.

SHAPE Australia Corporation Limited reported a robust half-year performance with a 48.5% rise in net profit and declared a fully franked 14 cent interim dividend, underpinned by strategic acquisition and operational discipline.

Euro Manganese Inc. reported progress on its Chvaletice and Bécancour manganese projects, securing funding amendments and advancing permitting despite ongoing financial pressures. The company is positioned to benefit from growing demand for high-purity manganese in lithium-ion batteries amid evolving market dynamics.

Euro Manganese Inc. reported a net loss of $3.6 million for Q3 2025 and extended key financing milestones to June 2026, highlighting ongoing challenges in funding its Chvaletice Manganese Project.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.